|
JO3425B1
(ar)
|
2013-07-15 |
2019-10-20 |
Novartis Ag |
مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
|
|
WO2017035408A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Compounds for treatment of immune and inflammatory disorders
|
|
AR106018A1
(es)
|
2015-08-26 |
2017-12-06 |
Achillion Pharmaceuticals Inc |
Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
|
|
JP6994767B2
(ja)
*
|
2016-06-21 |
2022-01-14 |
エックス４ ファーマシューティカルズ， インコーポレイテッド |
Ｃｘｃｒ４阻害剤およびその使用
|
|
EP3808748B1
(en)
|
2016-06-21 |
2026-05-20 |
X4 Pharmaceuticals, Inc. |
Substituted piperidines as cxcr4-inhibitors
|
|
MX2018016046A
(es)
|
2016-06-27 |
2019-05-02 |
Achillion Pharmaceuticals Inc |
Quinazolina y compuestos indol para tratar trastornos medicos.
|
|
CN113444094B
(zh)
*
|
2016-07-20 |
2023-12-22 |
纳莹(上海)生物科技有限公司 |
一种荧光探针及其制备方法和用途
|
|
CA3053818A1
(en)
|
2017-03-01 |
2018-09-07 |
Achillion Pharmaceuticals, Inc. |
Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
|
|
BR112020002804A2
(pt)
|
2017-08-24 |
2020-07-28 |
Novo Nordisk A/S |
composição farmacêutica líquida, e, kit
|
|
HRP20251596T1
(hr)
*
|
2017-08-31 |
2026-01-30 |
Novartis Ag |
Nove upotrebe derivata piperidinil-indola
|
|
AU2019304216B2
(en)
*
|
2018-07-16 |
2022-06-02 |
Novartis Ag |
Chemical process for preparing phenylpiperidinyl indole derivatives
|
|
EP3841086B1
(en)
|
2018-08-20 |
2025-04-23 |
Achillion Pharmaceuticals, Inc. |
Pharmaceutical compounds for the treatment of complement factor d medical disorders
|
|
WO2020051538A1
(en)
|
2018-09-06 |
2020-03-12 |
Achillion Pharmaceuticals, Inc. |
Morphic forms of complement factor d inhibitors
|
|
JP7443375B2
(ja)
|
2018-09-06 |
2024-03-05 |
アキリオン ファーマシューティカルズ， インコーポレーテッド |
医学的障害の治療のための大環状化合物
|
|
WO2020069024A1
(en)
|
2018-09-25 |
2020-04-02 |
Achillion Pharmaceuticals, Inc. |
Morphic forms of complement factor d inhibitors
|
|
US12435150B2
(en)
|
2019-01-11 |
2025-10-07 |
Novartis Ag |
Anti-CD40 antibodies for use in treatment of hidradenitis suppurativa
|
|
EP3908279B1
(en)
|
2019-01-11 |
2024-08-28 |
Novartis AG |
Lta4h inhibitor for the treatment or prevention of hidradenitis suppurativa
|
|
MX2021011507A
(es)
|
2019-03-22 |
2021-12-15 |
Achillion Pharmaceuticals Inc |
Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
|
|
IL294521A
(en)
|
2020-02-18 |
2022-09-01 |
Novo Nordisk As |
glp-1 compounds and their uses
|
|
JP2023515073A
(ja)
|
2020-02-20 |
2023-04-12 |
アキリオン ファーマシューティカルズ， インコーポレーテッド |
補体因子ｄ媒介障害の処置用のヘテロアリール化合物
|
|
CN120168469A
(zh)
*
|
2020-05-18 |
2025-06-20 |
诺华股份有限公司 |
Lnp023的结晶形式
|
|
JP7293513B2
(ja)
|
2020-07-16 |
2023-06-19 |
ノバルティス アーゲー |
Ｂ因子阻害剤の使用方法
|
|
US11951101B2
(en)
|
2020-07-16 |
2024-04-09 |
Novartis Ag |
Methods of using factor B inhibitors
|
|
CN114057692B
(zh)
*
|
2020-08-07 |
2023-07-21 |
上海美悦生物科技发展有限公司 |
一种杂环类化合物、其制备方法及用途
|
|
KR20230049115A
(ko)
*
|
2020-08-07 |
2023-04-12 |
상하이 메이유에 바이오테크 디벨롭먼트 컴퍼니 리미티드 |
보체 인자 b 억제제 및 이의 약학적 조성물, 제조 방법 및 용도
|
|
CA3193488A1
(en)
|
2020-09-23 |
2022-03-31 |
Jason Allan Wiles |
Pharmaceutical compounds for the treatment of complement mediated disorders
|
|
CN116438170B
(zh)
*
|
2020-12-30 |
2024-12-13 |
江苏恒瑞医药股份有限公司 |
含氮桥杂环化合物、其制备方法及其在医药上的应用
|
|
US20240109861A1
(en)
*
|
2020-12-30 |
2024-04-04 |
Medshine Discovery Inc. |
Series of piperidine-substituted benzoic acid compounds, and use thereof
|
|
EP4277982A1
(en)
*
|
2021-01-14 |
2023-11-22 |
Alexion Pharmaceuticals, Inc. |
Macrocycle complement factor b inhibitors
|
|
CN117062810A
(zh)
*
|
2021-04-16 |
2023-11-14 |
正大天晴药业集团股份有限公司 |
一系列双环取代的芳香羧酸类化合物
|
|
WO2022234541A1
(en)
|
2021-05-07 |
2022-11-10 |
Novartis Ag |
Iptacopan for the treatment of atypical hemolytic uremic syndrome
|
|
PE20250114A1
(es)
*
|
2021-06-03 |
2025-01-16 |
Chinook Therapeutics Inc |
Compuestos indol sustituidos y metodos de uso de los mismos
|
|
US20240277689A1
(en)
|
2021-06-18 |
2024-08-22 |
Novartis Ag |
Method of treating an autoimmune hematological disorder
|
|
WO2023278698A1
(en)
*
|
2021-06-30 |
2023-01-05 |
Apellis Pharmaceuticals, Inc. |
Complement inhibition
|
|
CN118043314A
(zh)
|
2021-08-18 |
2024-05-14 |
西藏海思科制药有限公司 |
一种苯并氮杂芳环衍生物及其在医药上的应用
|
|
JP2024530344A
(ja)
*
|
2021-09-07 |
2024-08-16 |
ノバルティス アーゲー |
加齢黄斑変性の処置のためのｂ因子阻害剤の使用
|
|
AU2022376760A1
(en)
*
|
2021-10-27 |
2024-05-02 |
Hansoh Bio Llc |
Piperidinyl indole derivatives, preparation methods and medicinal uses thereof
|
|
PE20242005A1
(es)
|
2022-01-24 |
2024-10-03 |
Novartis Ag |
Derivados espirociclicos de piperidinilo como inhibidores del factor b del complemento y usos de los mismos
|
|
EP4471021A4
(en)
*
|
2022-01-26 |
2025-04-30 |
Shanghai Meiyue Biotech Development Co., Ltd. |
Salt type and crystal form of complement factor b inhibitor, and preparation method therefor and application thereof
|
|
TW202342048A
(zh)
|
2022-02-28 |
2023-11-01 |
瑞士商諾華公司 |
使用ｌｏｕ０６４治療化膿性汗腺炎之方法
|
|
WO2023166487A1
(en)
|
2022-03-04 |
2023-09-07 |
Novartis Ag |
Use of iptacopan for the treatment of lupus nephritis
|
|
WO2023187715A1
(en)
|
2022-04-01 |
2023-10-05 |
Novartis Ag |
Complement factor b inhibitors and uses thereof
|
|
CN119698414A
(zh)
*
|
2022-06-20 |
2025-03-25 |
深圳信立泰药业股份有限公司 |
一种吲哚-苯基哌啶化合物及其制备方法与应用
|
|
CN119546585A
(zh)
*
|
2022-06-23 |
2025-02-28 |
上海济煜医药科技有限公司 |
吲哚化合物的制备、应用及用途
|
|
CN117327070A
(zh)
*
|
2022-06-30 |
2024-01-02 |
江苏恒瑞医药股份有限公司 |
一种含氮桥杂环衍生物的晶型及其制备方法
|
|
KR20250027806A
(ko)
*
|
2022-06-30 |
2025-02-27 |
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 |
질소 함유 브릿지 헤테로시클릭 유도체의 약학적으로 허용 가능한 염, 결정형 및 이의 제조 방법
|
|
WO2024046277A1
(zh)
*
|
2022-08-29 |
2024-03-07 |
南京明德新药研发有限公司 |
一系列含氮桥杂环化合物及其制备方法
|
|
TW202423426A
(zh)
*
|
2022-08-31 |
2024-06-16 |
美商奇努克醫療股份有限公司 |
經取代之吲哚化合物及其使用方法
|
|
JP2025530222A
(ja)
|
2022-09-10 |
2025-09-11 |
江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 |
２－置換ピペリジン誘導体、その製造方法及び医薬的用途
|
|
CN118026998A
(zh)
|
2022-11-11 |
2024-05-14 |
上海医药工业研究院有限公司 |
哌啶取代的苯甲酸类化合物、其药物组合物和应用
|
|
US20260159497A1
(en)
*
|
2022-11-14 |
2026-06-11 |
Novartis Pharma Ag |
Solid forms of a complement factor b inhibitor
|
|
CN120303261A
(zh)
*
|
2022-11-29 |
2025-07-11 |
上海济煜医药科技有限公司 |
苯并螺环吲哚化合物的制备、应用及用途
|
|
WO2024141011A1
(zh)
*
|
2022-12-31 |
2024-07-04 |
深圳晶泰科技有限公司 |
补体因子b抑制剂及其药物组合物和应用
|
|
WO2024148274A1
(en)
*
|
2023-01-05 |
2024-07-11 |
Apellis Pharmaceuticals, Inc. |
Complement inhibition
|
|
TW202434240A
(zh)
|
2023-02-22 |
2024-09-01 |
大陸商西藏海思科製藥有限公司 |
苯並氮雜芳環衍生物的藥物組合物及其在醫藥上的應用
|
|
AU2024226444A1
(en)
|
2023-02-23 |
2025-07-24 |
Novartis Ag |
Methods of using factor b inhibitors
|
|
CN118684668A
(zh)
*
|
2023-03-21 |
2024-09-24 |
上海美悦生物科技发展有限公司 |
螺环类化合物及其药物组合物、制备方法和用途
|
|
AU2024261191A1
(en)
|
2023-04-27 |
2025-11-06 |
Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
Salt of piperidylindole compound and preparation method therefor
|
|
CN121752557A
(zh)
|
2023-07-04 |
2026-03-27 |
希塔拉生物有限公司 |
2-(1h-吲哚-4-基)甲基)-异吲哚啉衍生物作为因子b抑制剂
|
|
EP4739390A1
(en)
|
2023-07-04 |
2026-05-13 |
Sitala Bio Ltd |
2-(1h-indol-4-yl)methyl)2h-indazole derivatives as factor b inhibitors
|
|
WO2025008516A2
(en)
|
2023-07-06 |
2025-01-09 |
Sitala Bio Ltd |
Novel compounds
|
|
WO2025008517A1
(en)
|
2023-07-06 |
2025-01-09 |
Sitala Bio Ltd |
Indole derivatives with factor b inhibitory activity
|
|
CN119371402A
(zh)
|
2023-07-26 |
2025-01-28 |
上海美悦生物科技发展有限公司 |
螺环烯基类或氮杂烯基类化合物及其药物组合物、制备方法和用途
|
|
TW202508580A
(zh)
|
2023-08-25 |
2025-03-01 |
瑞士商諾華公司 |
使用因子b抑制劑之方法
|
|
TW202515541A
(zh)
|
2023-09-29 |
2025-04-16 |
瑞士商諾華公司 |
補體因子ｂ抑制劑及其用途
|
|
WO2025083621A1
(en)
|
2023-10-20 |
2025-04-24 |
Novartis Ag |
Treatment of hidradenitis suppurativa using anti-baff-r antibodies
|
|
CN122396492A
(zh)
*
|
2023-12-05 |
2026-07-14 |
西藏海思科制药有限公司 |
苯并氮杂芳环衍生物在治疗补体因子b介导的疾病中的用途
|
|
TW202532059A
(zh)
|
2023-12-29 |
2025-08-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
一種含氮橋雜環化合物的晶體及其製備方法
|
|
AU2024417894A1
(en)
*
|
2024-01-10 |
2026-07-30 |
Hebei Yiling Medicine Research Institute Co. Ltd. |
Piperidinyl indole derivative, preparation method therefor and use thereof
|
|
WO2025172535A1
(en)
|
2024-02-15 |
2025-08-21 |
Sitala Bio Ltd |
Indole and benzimidazole compounds as factor b inhibitors
|
|
WO2025172910A1
(en)
|
2024-02-16 |
2025-08-21 |
Novartis Ag |
Factor b inhibitors for treatment of anca-associated vasculitis
|
|
TW202600134A
(zh)
*
|
2024-03-08 |
2026-01-01 |
大陸商江蘇豪森藥業集團有限公司 |
一種多元螺環化合物的鹽及其晶型、其製備方法和醫藥用途
|
|
TW202611049A
(zh)
*
|
2024-05-11 |
2026-03-16 |
香港商禮邦醫藥（香港）有限公司 |
補體因子b抑制劑
|
|
WO2025252133A1
(zh)
*
|
2024-06-07 |
2025-12-11 |
润尔眼科药物（广州）有限公司 |
一种含吲哚基团的化合物及其用途
|
|
WO2025256647A1
(zh)
*
|
2024-06-14 |
2025-12-18 |
润尔眼科药物（广州）有限公司 |
化合物及其医药用途
|
|
WO2026002007A1
(zh)
*
|
2024-06-25 |
2026-01-02 |
珠海联邦制药股份有限公司 |
补体因子b抑制剂及其药物组合物和应用
|
|
WO2026003809A1
(en)
|
2024-06-29 |
2026-01-02 |
Assia Chemical Industries Ltd. |
Solid state forms of iptacopan hydrochloride
|
|
WO2026008074A1
(zh)
*
|
2024-07-05 |
2026-01-08 |
南京正大天晴制药有限公司 |
补体因子b抑制剂的晶型、其制备方法及用途
|
|
WO2026042088A1
(en)
*
|
2024-08-21 |
2026-02-26 |
Zydus Lifesciences Limited |
Trycyclic derivatives and their use as complement factor b inhibitors
|
|
WO2026069246A1
(en)
|
2024-09-30 |
2026-04-02 |
Novartis Ag |
Complement factor b inhibitors and uses thereof
|
|
WO2026086939A1
(zh)
*
|
2024-10-25 |
2026-04-30 |
上海美悦生物科技发展有限公司 |
杂环化合物在制备预防或治疗IgA肾病的药物中的用途
|
|
WO2026093943A1
(en)
|
2024-10-31 |
2026-05-07 |
Novartis Ag |
Chemical process for preparing phenylpiperidinyl indole derivatives
|
|
GB202500206D0
(en)
|
2025-01-08 |
2025-02-19 |
Sitala Bio Ltd |
Novel compounds
|